IQVIA Named Best Contract Research Organization Full-Service Provider in 2018 Scrip Awards
IQVIA’s Innovative Technology, Advanced Analytics and Industry Expertise Demonstrate the Value of Its CORE to Industry Partners
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (NYSE:IQV) today announced that it was awarded the 2018 Scrip Award for Best Contract Research Organization — Full-Service Provider. This marks the seventh time in the last 10 years that the company has received this award.
“We are honored to receive this award which recognizes our commitment to build strong, collaborative partnerships with our clients using CORE-enabled solutions,” said Richard Staub, president, Research & Development Solutions at IQVIA. “Using our innovative technology, analytics-driven insights and deep clinical expertise, we are proud to help our clients drive healthcare innovations forward in novel ways.”
IQVIA’s approach to clinical development leverages real world evidence-driven design capabilities to overcome the root causes of trial inefficiencies that have plagued the industry for many years. At the heart of IQVIA’s solutions is the IQVIA CORE™ which pairs transformative technology and advanced analytics with IQVIA’s deep therapeutic and scientific expertise to analyze a vast amount of real-world data.
The Best Contract Research Organization — Full-Service Provider award acknowledges the critical role that CROs play in drug development. Nominees are judged on the quality of services and relationships that they have built with clients and the innovative patient recruitment strategies they have implemented.
An independent panel of 17 life sciences experts judged the nominations, and the winners were announced at the 14th Annual Scrip Awards Ceremony in London November 28. Hosted by Pharma Intelligence, a top team of journalists, researchers and analysts, the Scrip Awards recognize excellence within the biopharmaceutical industry.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.